Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

This study has been completed.
Sponsor:
Collaborator:
Mie University
Information provided by:
Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier:
NCT00291473
First received: February 10, 2006
Last updated: March 2, 2009
Last verified: March 2009
  Purpose

Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens. Nine patients will be enrolled, who are refractory to standard therapies for cancer or at high risk to relapse. CHP-HER2 and CHP-NY-ESO-1 are subcutaneously given on bimonthly basis, together with OK-432(Picibanil) as an immunoadjuvant. Six doses will be given. Toxicity profiles will be monitored, and antigen specific humoral anad T cell responses will be described.


Condition Intervention Phase
Esophageal Cancer
Lung Cancer
Stomach Cancer
Breast Cancer
Ovarian Cancer
Drug: CHP-HER2, CHP-NY-ESO-1
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers

Resource links provided by NLM:


Further study details as provided by Ludwig Institute for Cancer Research:

Primary Outcome Measures:
  • adverse events

Secondary Outcome Measures:
  • immune responses including HER2 and NY-ESO-1 specific IgG and T cells

Estimated Enrollment: 9
Study Start Date: July 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histological confirmation of cancer.
  2. HER2 expression in tumor cells scored as 1+ or more which should be confirmed by IHC using at least two antibodies (archived issue; see Appendix 1 and Reference 1 for methodology).

    or NY-ESO-1 expression by reverse transcriptase and polymerase chain reaction (RT-PCR) analysis (Appendix 2), preferably, or immunohistochemistry

  3. Patients must

    1. are at high risk of recurrence, more than 25% of probability, after complete resection or even after post-operative adjuvant treatment, and effective adjuvant therapy is not available or refused; or
    2. have metastatic disease, and treatment has failed, or in the situation where effective therapy is not available, or has been refused.
  4. Complete recovery from surgery (at least 4 weeks).
  5. Laboratory values within the following limits:

    Hemoglobin 9.0 g/dL or more, or 10.0 g/dL or more if <50 kg Neutrophil count >1.5 x 109/L Lymphocyte count >0.5 x 109/L Platelet count >100 x 109/L Serum creatinine ≤ 1.8 mg/dL Serum bilirubin ≤ 2 mg/dL

  6. Performance status > 70 (Karnofsky Scale) and life expectancy >3 months.
  7. Age 18 years or more.

Exclusion Criteria:

  1. Clinically significant heart disease (NYHA Class III or IV).
  2. Cardiac dysfunction; less than 50% of ejection fraction by echocardiogram.
  3. Immunodeficiency disease.
  4. Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.
  5. Previous bone marrow or stem cell transplant.
  6. Metastatic disease to the central nervous system, unless treated and stable.
  7. known HIV antibody positivity.
  8. Anaphylactic reaction to previous vaccination.
  9. Hypersensitivity to penicillin
  10. Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before study entry (6 weeks for nitrosoureas).
  11. Concomitant treatment with steroids. Topical or inhalational steroids are permitted.
  12. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
  13. Pregnancy or nursing .
  14. Refusal, by women of childbearing potential, to use medically acceptable means of contraception.
  15. Mental impairment that may compromise the ability to give informed consent.
  16. Lack of availability for immunological and clinical follow-up assessment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00291473

Locations
Japan
Mie University Hospital
Tsu, Mie, Japan, 514-8507
Sponsors and Collaborators
Ludwig Institute for Cancer Research
Mie University
Investigators
Principal Investigator: Hiroshi Shiku, M.D. Mie University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00291473     History of Changes
Other Study ID Numbers: LMT2004-011
Study First Received: February 10, 2006
Last Updated: March 2, 2009
Health Authority: Japan: Ethics Committee in Mie University

Additional relevant MeSH terms:
Breast Neoplasms
Esophageal Neoplasms
Lung Neoplasms
Stomach Neoplasms
Ovarian Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Stomach Diseases
Endocrine Gland Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders

ClinicalTrials.gov processed this record on July 22, 2014